Literature DB >> 22778311

American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology.

D Andrew Loblaw1, Ann Alexis Prestrud, Mark R Somerfield, Thomas K Oliver, Melissa C Brouwers, Robert K Nam, Gary H Lyman, Ethan Basch.   

Abstract

The American Society of Clinical Oncology (ASCO) guidelines program employs a systematic review-based methodology to produce evidence-based guidelines. This is consistent with the stance of the Institute of Medicine on guideline development, which is that high-quality evidence syntheses form the basis for recommendation development. In the absence of high-quality evidence, recommendation development becomes more complex. One option is to provide no recommendations or withdraw a guideline topic. However, it is often the areas of greatest uncertainty in which the evidentiary base is incomplete, and thus, guidelines are needed most. To provide recommendations in such circumstances, an explicit methodology is needed to ensure that a credible process is undertaken, and rigorous, reliable advice is provided. In 2010, the ASCO Board of Directors approved development of guideline recommendations using consensus methodology. A modified Delphi approach to recommendation development, based on the best available data identified in a systematic review, was piloted with an ASCO guideline. Consensus was achieved through the rating of a series of recommendations by a large group of clinicians, including academic and community-based content and methodology experts. A prespecified threshold of agreement was determined to indicate when consensus was achieved. Consensus was defined as agreement by ≥ 75% of raters. The formal consensus methodology used by ASCO enabled development of guideline recommendations on a challenging clinical issue based on limited evidence using a rigorous, transparent, and explicit method. This methodology is proposed for development of future ASCO guidelines on topics for which limited evidence is available.

Mesh:

Year:  2012        PMID: 22778311     DOI: 10.1200/JCO.2012.42.0489

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  48 in total

1.  Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice.

Authors:  David E Cohn; Laura J Havrilesky; Kathryn Osann; Joseph Lipscomb; Susie Hsieh; Joan L Walker; Alexi A Wright; Ronald D Alvarez; Beth Y Karlan; Robert E Bristow; Paul A DiSilvestro; Mark T Wakabayashi; Robert Morgan; Dana B Mukamel; Lari Wenzel
Journal:  Gynecol Oncol       Date:  2015-07-12       Impact factor: 5.482

2.  Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey.

Authors:  Paolo Bossi; Gianmauro Numico; Vitaliana De Santis; Maria Grazia Ruo Redda; Alessia Reali; Liliana Belgioia; Maria Cossu Rocca; Ester Orlandi; Mario Airoldi; Alamalina Bacigalupo; Marta Mazzer; Gabriella Saibene; Elvio Russi
Journal:  Support Care Cancer       Date:  2014-02-25       Impact factor: 3.603

3.  Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies.

Authors:  J Gagnon; E Lévesque; F Borduas; J Chiquette; C Diorio; N Duchesne; M Dumais; L Eloy; W Foulkes; N Gervais; L Lalonde; B L'Espérance; S Meterissian; L Provencher; J Richard; C Savard; I Trop; N Wong; B M Knoppers; J Simard
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

4.  Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.

Authors:  Scott C Morgan; Karen Hoffman; D Andrew Loblaw; Mark K Buyyounouski; Caroline Patton; Daniel Barocas; Soren Bentzen; Michael Chang; Jason Efstathiou; Patrick Greany; Per Halvorsen; Bridget F Koontz; Colleen Lawton; C Marc Leyrer; Daniel Lin; Michael Ray; Howard Sandler
Journal:  J Clin Oncol       Date:  2018-10-11       Impact factor: 44.544

5.  American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care.

Authors:  Mary S McCabe; Smita Bhatia; Kevin C Oeffinger; Gregory H Reaman; Courtney Tyne; Dana S Wollins; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

6.  Users' guide to the surgical literature: how to evaluate clinical practice guidelines.

Authors:  Christopher J Coroneos; Sophocles H Voineskos; Sylvie D Cornacchi; Charlie H Goldsmith; Teegan A Ignacy; Achilleas Thoma
Journal:  Can J Surg       Date:  2014-08       Impact factor: 2.089

7.  The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.

Authors:  S Robinson; P Dreger; D Caballero; P Corradini; C Geisler; M Ghielmini; S Le Gouill; E Kimby; S Rule; U Vitolo; M Dreyling; O Hermine
Journal:  Leukemia       Date:  2014-07-18       Impact factor: 11.528

Review 8.  Guidelines for Perioperative Care for Liver Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations.

Authors:  Emmanuel Melloul; Martin Hübner; Michael Scott; Chris Snowden; James Prentis; Cornelis H C Dejong; O James Garden; Olivier Farges; Norihiro Kokudo; Jean-Nicolas Vauthey; Pierre-Alain Clavien; Nicolas Demartines
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

Review 9.  A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).

Authors:  A González; A Lluch; E Aba; J Albanell; A Antón; I Álvarez; F Ayala; A Barnadas; L Calvo; E Ciruelos; J Cortés; J de la Haba; J M López-Vega; E Martínez; M Muñoz; I Peláez; A Redondo; Á Rodríguez; C A Rodríguez; A Ruíz; A Llombart
Journal:  Clin Transl Oncol       Date:  2016-11-16       Impact factor: 3.405

10.  Consensus on international guidelines for management of groin hernias.

Authors:  Nadine van Veenendaal; Maarten Simons; William Hope; Sathien Tumtavitikul; Jaap Bonjer
Journal:  Surg Endosc       Date:  2020-04-06       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.